Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | HTT | P42858 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.49 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.49 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.49 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.49 |
| ▸ | UGT1A7 | Q9HAW7 | 1/20 | 0.49 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5448485 | 0.88 | TAS2R14 (0.61) | LMNAALDH1A1TAS2R14MEN1KMT2A | |
| SCHEMBL5466187 | 0.87 | CA9 (0.67) | SMN1; SMN2RAB9ATAS2R14CA12CA2 | |
| SCHEMBL5459724 | 0.85 | ALDH1A1 (0.46) | LMNAHTTSMN1; SMN2ALDH1A1TAS2R14 | |
| SCHEMBL394849 | 0.84 | LMNA (0.53) | LMNAHTTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL2514583 | 0.82 | ALDH1A1 (0.54) | LMNAHTTSMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL5024746 | 0.80 | LMNA (0.70) | LMNAHTTSMN1; SMN2RAB9ANPC1 | |
| Etebenecid SCHEMBL1643610 | 0.79 | SMN1; SMN2 (0.75) | LMNAHTTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL165384 | 0.78 | PSIP1 (0.57) | LMNAHTTALDH1A1HPGDCA2 | |
| SCHEMBL4186041 | 0.78 | HTT (0.54) | LMNAHTTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL13365527 | 0.77 | LMNA (0.66) | LMNAHTTSMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| EP-1451172-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | AstraZeneca AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003037887-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | HTR1B, HTR1D, HTR1A | LMNA 1833/4885HTT 322/4885SMN1; SMN2 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.